B -- Clinical Translation Efforts of Cancer Nanotechnology Initiatives

The National Cancer Institute (NCI), Office of Technology and Industrial Relations, Office of Nanotechnology plans to procure the consultancy services from Meena Augustus for the Clinical Translation Efforts of Cancer Nanotechnology Initiatives. For several years, the National Cancer Institute (NCI) has supported exploratory work integrating nanotechnology into cancer research. The NCI is moving the science of nanotechnology into the clinic to change the way we diagnose, treat and prevent cancer. Today, nanodevices are used in detecting cancer at its earliest stages, pinpointing its location within the body, delivering anticancer drugs specifically to malignant cells, and determining if these drugs are killing malignant cells. As research continues and nanodevices are evaluated for safety and efficacy, nanotechnology will result in significant advances in early detection, molecular imaging, assessment and therapeutic efficacy, targeted and multi functional therapeutics, and the prevention and control of cancer. The nanotechnology is capable of contributing to solutions of mission critical problems in cancer research. The NCI's ultimate goal is to implement the components of the Alliance and catalyze targeted discovery and development efforts that offer the greatest opportunity for advances in the near and medium terms and to lower the barriers for those advances to be handed off to the private sector for commercial development. Ms Augustus is a recognized professional with experience in providing support and consultant services in developing engineered nanotechnologies as targeted cancer therapeutic and imaging agents. She has substantial experience with developing dialogs on contract research with a unique knowledge to support the work directed towards the evaluation of early stage companies focused on developing nanotechnology based therapies. She has been instrumental in developing dialogs on contract research and collaborations with major US, UK and other global Pharma and Biotech companies like Amgen, Astra, Zeneca, HGS and key US academic, medical and research institutions. Dr. Augustus has extensive experience and knowledge on the business development methodologies that are essential for gaining valuable insights in the projects listed above. The methodologies include exploring market potential in the US for therapeutic (cancer) device, a non invasive Rotational Field Quantum Magnetic Resonance based device. Additionally, she was an adviser to a start up company to bring to marker a non invasive cardiovasular disease detection and screening device, developed and in use in UK and Europe, FDA approved for research purposes in the US. Dr. Augustus understands the engineered nanotechnologies as targeted cancer therapeutics and imagning agents and the role of the products in contributing to finding solutions of mission critical problems in cancer research. Therefore, to meet the goal to develop and utilize nanomaterials and nanoscale devices technologies within the cancer research as described above this work can only be completed by Meena Augustus. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13. The North American Industry Classification System code is 541990 and the business size standard is $6.5M. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party has the unique capabilities, resources and personnel to perform the requirement. An oringinal and one copy of the capability statements must be received in the contracting office by 1:00 PM EDT, on September 20, 2007. Faxed and emailed capability statements are NOT authorized. For further information please contact Deborah Moore, Contract Specialist via electronic mail at dm170b@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA).